CEA

CEA
Name	Carcinoembryonic antigen
Acronym	CEA
Type	Oncofetal glycoprotein
Gene	CEACAM5
Family	Carcinoembryonic antigen family
Discovered	1965
Discovered by	Phil Gold; Samuel O. Freedman
Clinical use	Tumor marker for colorectal cancer, other adenocarcinomas

CEA

Carcinoembryonic antigen is an oncofetal glycoprotein widely measured as a tumor marker in clinical oncology. It is produced by epithelial cells of the gastrointestinal tract during fetal development and by several adenocarcinomas in adults, and its serum concentration is used to assist management of patients with malignancies. Laboratories, oncology centers, surgical departments, and pathology services commonly incorporate measurements of this antigen into surveillance protocols and clinical trials.

Definition and Nomenclature

The molecule is officially designated by the gene symbol CEACAM5 and is a member of the carcinoembryonic antigen-related cell adhesion molecule family, first characterized in studies from the 1960s at McGill University by Phil Gold and Samuel O. Freedman. Nomenclature appears across literature under synonyms such as carcinoembryonic antigen, carcinoembryonic glycoprotein, and CEACAM5; gene and protein databases maintained by institutions like National Institutes of Health, European Molecular Biology Laboratory, and Online Mendelian Inheritance in Man catalog these entries. Clinical laboratory standards from organizations such as College of American Pathologists and guidelines from specialist societies like American Society of Clinical Oncology reference this antigen when outlining tumor marker panels.

Biochemical Structure and Genetics

The protein encoded by CEACAM5 is a glycosylated, membrane-associated immunoglobulin superfamily member with an N-terminal domain and multiple Ig-like domains; structural analyses have been reported in journals affiliated with American Association for Cancer Research and Nature Publishing Group. The gene maps to chromosome 19 alongside paralogous genes in the CEACAM cluster, which also includes CEACAM1 and CEACAM6, loci studied by research groups at universities including Harvard University and Massachusetts Institute of Technology. Post-translational glycosylation patterns added in the endoplasmic reticulum and Golgi apparatus influence antigenicity; such biochemical characterization is detailed in reports from Cold Spring Harbor Laboratory and reviews in Journal of Biological Chemistry. Polymorphisms and alternative splicing affecting expression have been explored in population cohorts assembled by UK Biobank and consortia such as The Cancer Genome Atlas.

Clinical Uses and Diagnostic Utility

Clinical applications center on monitoring disease course in patients with colorectal adenocarcinoma following interventions performed at centers like Mayo Clinic and Memorial Sloan Kettering Cancer Center. Measurement is performed in serum by immunoassays standardized by manufacturers and regulated by agencies such as Food and Drug Administration and European Medicines Agency; commercial assays are developed by companies including Roche and Abbott Laboratories. Professional guidelines from societies like European Society for Medical Oncology and American College of Surgeons discuss thresholds used for surveillance, perioperative risk stratification, and as adjuncts to imaging modalities such as computed tomography performed at hospitals like Johns Hopkins Hospital.

Interpretation, Limitations, and False Results

Interpretation requires context provided by oncology multidisciplinary teams at institutions like Dana-Farber Cancer Institute and Cleveland Clinic. Elevated concentrations can result from benign conditions and lifestyle factors observed in cohorts studied by Framingham Heart Study investigators and may be influenced by tobacco exposure documented in studies from Centers for Disease Control and Prevention. Analytical limitations include assay heterogeneity, heterophile antibodies, and biological variability discussed in standards from Clinical and Laboratory Standards Institute; false positives and false negatives have been reported in trials sponsored by cooperative groups such as National Cancer Institute networks. For screening asymptomatic populations, major bodies including U.S. Preventive Services Task Force advise against reliance on this antigen alone.

Role in Specific Cancers

High relevance exists in colorectal adenocarcinoma management, with perioperative and surveillance utility reported by surgical oncology groups at St. Mark's Hospital and outcomes analyses in journals affiliated with American Society of Clinical Oncology. Elevated levels are also encountered in pancreatic cancer cohorts treated at MD Anderson Cancer Center, gastric cancer series from Seoul National University Hospital, lung adenocarcinoma described in studies from University of Tokyo, and breast and ovarian malignancies evaluated by teams at Royal Marsden Hospital and European Institute of Oncology. Patterns of expression and prognostic associations have been examined across registries such as Surveillance, Epidemiology, and End Results Program and in translational studies conducted at institutes like Salk Institute.

Historical Development and Research Directions

Discovery reported in the 1960s by investigators at McGill University led to rapid adoption in clinical oncology through the 1970s and 1980s, with validation studies from cancer centers including UCLA and University of Pennsylvania. Ongoing research directions include improving assay specificity through monoclonal antibody engineering pioneered at institutions like Scripps Research and developing targeted therapies exploiting CEACAM5 expression pursued by pharmaceutical collaborations with companies such as GlaxoSmithKline and Bristol Myers Squibb. Current translational and basic science work leverages datasets from consortia including International Cancer Genome Consortium and incorporates techniques refined at Broad Institute and European Bioinformatics Institute to explore immunotherapy targets, circulating tumor DNA correlation, and multimodal biomarker panels.

Category:Biomarkers